期刊文献+

吉兰-巴雷综合征患者血浆置换与注射免疫球蛋白治疗的疗效比较 被引量:12

Comparison on therapeutic effect of plasma exchange and Intravenous Immunoglobulin for Guillian-Barre Syndrome
下载PDF
导出
摘要 目的分析血浆置换(PE)与静脉注射免疫球蛋白(IVIg)在治疗吉兰-巴雷综合征(GBS)的过程中临床疗效的差异。方法 64例GBS患者分别进行PE与IVIg治疗,观察治疗前及治疗后患者神经功能改善状况。结果 PE治疗的GBS患者神经功能改善情况优于IVIg组,且临床效果显现时间早于IVIg组,治疗2 w后两组的有效率分别是96%和79%,PE治疗效果优于IVIg组。结论 PE可有效改善患者症状,有利于患者病情的早期康复。 Objective To observe and compare the clinical curative effect of the plasma exchange (PE) and Intra- venous Immunoglobulin (IVlg) for Guillian-Barrc Syndrome (GBS). Methods Overall, 64 adult patients with GBS for PE and IVIg treatment, respectively, and nerve function were observed pre-treatment and at 1 week/2 weeks after completion of treatment. Results After plasma exchange treatment,nerve function appeared to improve better than the IVlg group and clinical effect was better than the IVIg group. Treatment effective rates of the two groups after 2 weeks, respectively, were 96% and 79%. The curative effect of PE were better than the IVIg group. Conclusion PE treatment has a more signifi- cantly curative effect, as it can effectively improve symptoms and be helpful in the early rehabilitation of patients.
作者 叶芸 李苏亮
出处 《中风与神经疾病杂志》 CAS 北大核心 2015年第9期808-810,共3页 Journal of Apoplexy and Nervous Diseases
基金 陕西省教育厅科技项目(09JK714)
关键词 吉兰-巴雷综合征 血浆置换 静脉注射免疫球蛋白 Guillian-Barre Syndrome Plasma exchange Intravenous Immunoglobulin
  • 相关文献

参考文献12

  • 1Lu L,Luo G, Xiao F. A retrospective survey of the quality of reports and their correlates among randomized controlled trials of immunother- apy for Guillain-Barr6syndrome [ J ]. Immunotherapy, 2013,5 : 829- 836.
  • 2Akbayram S, Do an M, Akgtin C, et al. Clinical features and prognosis with Guillain-Barr6syndrome [ J ] Ann Indian Acad Neurol,2011,14: 98-102.
  • 3Dimachkie MM, Barohn RJ. Guillain-Barrrsyndromeand variants [ J ]. Neurol Clin,2013,31:491-510.
  • 4Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barr6 syndrome[J]. Ann Neurol,1990,27:S21-24.
  • 5Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline up- date:Plasmapheresis in neurologic disorders:report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology[J]. Neurology,2011,76:294-300.
  • 6Naphade PU, Verma R, Garg RK, et aL Prevalence of bladder dys- function, urodynamic findings, and their correlation with outcome in Guillain-Barre syndrome [ J ]. Neurourol Urodyu, 2012, 31 : 1135- 1140.
  • 7Verma R, Chaudhari TS, Raut TP,et al. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syn- drome (GBS)[J]. J Neurol Sci,2013,335:105-111.
  • 8Kleyweg RP, van der Mech6 FG, Sehmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guil- lain-Barr6 syndrome [ J ]. Muscle Nerve, 1991,14 : 1103-1109.
  • 9Rosch RE, Bamford A, Hacohen Y, et al. Guillain-Barr6 syndrome as- sociated with CASPR2 antibodies: two paediatric cases [ J ]. J Peripber Nerv Syst,2014,19 : 246 -249.
  • 10Coll-CantiJ, Alvarez-Ramo R, Dorado L, et al. Guillain-Barre syn- drome and IVIg : does early initiation of treatment influence the mean hospital stay[ J]. Neurologia,2009,24:217-219.

同被引文献69

引证文献12

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部